2019
DOI: 10.1155/2019/9853701
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objectives. Despite the fact that it is widely acknowledged that immune checkpoint inhibitors (ICIs) rely on the presence of immune response to take their antitumor effect, little is known whether there is an influence exerted on the efficacy of ICIs based on patients’ age. We performed a systematic review and meta-analysis to explore the efficacy of ICIs between younger and older patients. Materials and Methods. We searched online database and major conference proceedings for randomized controlled trials (RCT… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
22
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(23 citation statements)
references
References 48 publications
1
22
0
Order By: Relevance
“…Third, older patients (≥65) were found to undergo HPD during ICI treatment more often than younger patients and had a worse prognosis [12]. Many randomized controlled trials also reported that less benefit was obtained by older patients than by younger patients, which validated that age plays a role in immunotherapy [82]. The mechanisms connecting HPD and advanced age remain unclear.…”
Section: Clinical Indicators Of Hpdmentioning
confidence: 99%
“…Third, older patients (≥65) were found to undergo HPD during ICI treatment more often than younger patients and had a worse prognosis [12]. Many randomized controlled trials also reported that less benefit was obtained by older patients than by younger patients, which validated that age plays a role in immunotherapy [82]. The mechanisms connecting HPD and advanced age remain unclear.…”
Section: Clinical Indicators Of Hpdmentioning
confidence: 99%
“…The interest in the factors to predict response and incidence of immune-related adverse events (irAEs) has grown in recent years, given the exponential growth of immune checkpoint inhibitors (ICIs) used in clinical practice. Tumor mutational burden, level of programmed death-ligand 1 (PD-L1) expression, microsatellite instability (MSI), baseline size of the primary tumor, and type of the cancer are some of the clinical factors that have limited utility in predicting the response to ICIs; however, there are no well-established factors that can predict the irAE [1][2][3][4][5]. The value of pretreatment complete blood counts, including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), or platelet-to-lymphocyte ratio (PLR), for this purpose is equivocal.…”
Section: Introductionmentioning
confidence: 99%
“…Another systematic review and meta-analysis including 12 randomized clinical trials revealed that immune checkpoint inhibitors can improve OS for patients with advanced lung cancer when compared to controls and the magnitude of benefit in OS had comparable efficacy in both younger and older arms using a cut-off of 65 years. Conversely, older patients failed to acquire benefit from immunotherapy when subdivided with a further cut-off of 75 years (6). Focusing on survival outcomes in predefined age groups, nivolumab versus docetaxel achieved a reduction of the risk of death in the subset of patients between the ages 65-75 years of 44% in CheckMate 017 [hazard ratio (HR) 0.56] and 37% in CheckMate 057 study (HR 0.63), while it seemed to be less effective than chemotherapy in patients aged 75 years or older (HR 1.76 and 0.90, respectively).…”
mentioning
confidence: 99%